AVITA Medical, Inc. (RCEL) Tops Q4 EPS by 10c ; Offers Guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q4 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $14.43 million.

GUIDANCE:

AVITA Medical, Inc. sees Q1 2024 revenue of $14.8-15.6 million, versus the consensus of $14.3 million.

AVITA Medical, Inc. sees FY2024 revenue of $78.5-84.5 million, versus the consensus of $71.98 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Humana reaffirms 2026 earnings guidance ahead of investor meetings
• Yext, Inc. (YEXT) Tops Q2 EPS by 4c